Clinical Trial Update: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for MRG002 in HER2-positive unresectable locally advanced or metastatic urothelial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer
• Urothelial Carcinoma

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | Phase 2 | Status: UNKNOWN